Robert Nelsen

Robert Nelsen

Founder presso SANA BIOTECHNOLOGY, INC.

Patrimonio netto: 7 M $ in data 29/02/2024

60 anni
Health Technology
Commercial Services
Finance

Profilo

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.
Some of his notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), June Therapeutics (JUNO – acquired by Celgene), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX), Altos Labs, EQRx (EQRX), National Resilience, Prime Medicine, Lyell Immunopharma (LYEL), Array BioPharma (ARRY – acquired by Pfizer), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Receptos (RCPT – acquired by Celgene), Aviron (AVIR – acquired by MedImmune), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (VERV), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic), Caliper Life Sciences (CALP – acquired by PerkinElmer), Trubion Pharmaceuticals (TRBN – acquired by Emergent Biosolutions), Adolor (ADLR – acquired by Cubist Pharmaceuticals), deCODE Genetics (DCGN – acquired by Amgen), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex Pharmaceuticals), Element, and IDUN Pharmaceuticals (acquired by Pfizer).
Mr. Nelsen is a director of VIR, SANA, LYEL, National Resilience, Insitro, Prime Medicine, Nutcracker Therapeutics, Neumora Therapeutics, Brii Biosciences, and serves as Chairman of Hua Medicine, among others.
He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute of Systems Biology, and was a director of the National Venture Capital association.
Mr. Nelsen holds an M.B.A.
from the University of Chicago and a B.S.
from the University of Puget Sound with majors in Economics and Biology.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
22/05/2023 610 041 ( 0.45% ) 7 M $ 29/02/2024
08/02/2024 13 853 ( 0.01% ) 139 084 $ 29/02/2024
15/02/2024 16 080 ( 0.01% ) 138 770 $ 29/02/2024
30/06/2022 150 000 ( 0.01% ) 30 081 $ 29/02/2024

Posizioni attive di Robert Nelsen

SocietàPosizioneInizio
HUA MEDICINE (SHANGHAI) LTD. Chairman 23/04/2010
SANA BIOTECHNOLOGY, INC. Founder 13/07/2018
PRIME MEDICINE, INC. Director/Board Member 01/09/2020
VIR BIOTECHNOLOGY, INC. Founder 07/04/2016
LYELL IMMUNOPHARMA, INC. Director/Board Member 01/09/2018
BRII BIOSCIENCES LIMITED Director/Board Member 22/06/2018
Founder 28/06/2010
Director/Board Member -
Director/Board Member 01/01/2016
░░░░░ ░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
░░░░░░░░ ░░░░░░░░░░░ ░░░░ ░░░░░░░░ -
░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░░ ░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
Tutte le posizioni attive di Robert Nelsen

Precedenti posizioni note di Robert Nelsen

SocietàPosizioneFine
░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Robert Nelsen

Formazione di Robert Nelsen

University of Puget Sound Undergraduate Degree
The University of Chicago Booth School of Business Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Robert Nelsen

Relazioni

99

Relazioni di 1° grado

79

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa19
ILLUMINA, INC.

Health Technology

SIENNA BIOPHARMACEUTICALS, INC.

Health Technology

BRII BIOSCIENCES LIMITED

Commercial Services

LYELL IMMUNOPHARMA, INC.

Health Technology

PRIME MEDICINE, INC.

Health Technology

SANA BIOTECHNOLOGY, INC.

Health Technology

BEAM THERAPEUTICS INC.

Health Technology

GOSSAMER BIO, INC.

Health Technology

VIR BIOTECHNOLOGY, INC.

Health Technology

UNITY BIOTECHNOLOGY, INC.

Health Technology

AGIOS PHARMACEUTICALS, INC.

Health Technology

DENALI THERAPEUTICS INC.

Health Technology

SYROS PHARMACEUTICALS, INC.

Health Technology

HUA MEDICINE (SHANGHAI) LTD.

Health Technology

SAGE THERAPEUTICS, INC.

Health Technology

FATE THERAPEUTICS, INC.

Health Technology

CYCLACEL PHARMACEUTICALS, INC.

Health Technology

BELLEROPHON THERAPEUTICS, INC.

Health Technology

NEUMORA THERAPEUTICS, INC.

Health Technology

Aziende private58

Electronic Technology

Commercial Services

Health Technology

Health Technology

Finance

ARCH Venture Corp.

Finance

Process Industries

Health Technology

Health Technology

Commercial Services

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Energy Minerals

Health Technology

Health Technology

Producer Manufacturing

Miscellaneous

Consumer Services

Technology Services

Finance

Health Technology

Commercial Services

Commercial Services

Resilience, Inc.

Commercial Services

Commercial Services

Finance

Commercial Services

Saga Investments LLC

Finance

Commercial Services

Health Technology

Health Services

Health Technology

Commercial Services

Health Technology

Electronic Technology

Health Services

Health Technology

Technology Services

Health Technology

Hua Medicine Technology (Hong Kong) Ltd.

Health Services

Commercial Services

Commercial Services

Finance

Commercial Services

Brii Biosciences, Inc.

Brii Biosciences (Hong Kong) Co. Ltd.

Health Technology

Finance

Brii Biosciences (Beijing) Co. Ltd.

Health Technology

Health Technology

Health Services

Technology Services

Vedi le connessioni aziendali
  1. Borsa
  2. Insiders
  3. Robert Nelsen